evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,923 questions · 1,956 findings · 143 reviews · Musculoskeletal

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 555 · 28.4%GRADE not reported 107 · 5.5%Very low 255 · 13%Low 555 · 28.4%Moderate 357 · 18.3%High 127 · 6.5%

Vitamin C vs allopurinol

Acute gout attacks · participants with chronic gout and sUA level > 0.36mmol/L

The review found no eligible studies for this question.

1 finding from 1 review

Belimumab 10 mg/kg vs placebo

Reduction of at least 4 points in SELENA‐SLEDAI at 52 weeks SELENA‐SLEDAI score, a validated marker of SLE disease activity (range 0 to 105; higher score = worse disease activity) · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)

Belimumab 10 mg/kg leads to higher reduction of at least 4 points in SELENA‐SLEDAI at 52 weeks… compared with placebo (high certainty).

1 finding from 1 review

Belimumab 10 mg/kg vs placebo

Change in HRQOL, on SF‐36 PCS score at 52 weeks Improvement in SF‐36 PCS score from baseline ( · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)

Belimumab 10 mg/kg probably leads to higher change in HRQOL, on SF‐36 PCS score at 52 weeks Improvement in SF‐36… compared with placebo (moderate certainty).

1 finding from 1 review

Belimumab 10 mg/kg vs placebo

Reduction of glucocorticoid dose by at least 50% · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)

Belimumab 10 mg/kg leads to higher reduction of glucocorticoid dose by at least 50% compared with placebo (high certainty).

1 finding from 1 review

Belimumab 10 mg/kg vs placebo

Participants with one or more serious adverse events · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)

Belimumab 10 mg/kg showed no clear difference in participants with one or more serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Belimumab 10 mg/kg vs placebo

Participants with one or more serious infections · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)

Belimumab 10 mg/kg showed no clear difference in participants with one or more serious infections compared with placebo (moderate certainty).

1 finding from 1 review

Belimumab 10 mg/kg vs placebo

Withdrawals due to adverse events · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)

Belimumab 10 mg/kg showed no clear difference in withdrawals due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Belimumab 10 mg/kg vs placebo

Number of participants who died during the study · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)

Belimumab 10 mg/kg showed no clear difference in number of participants who died during the study compared with placebo (low certainty).

1 finding from 1 review

Autologous blood or PRP vs placebo at 3 months' follow‐up

Treatment success (> 25% improvement in pain or function) · lateral elbow pain

It is very uncertain whether autologous blood or PRP changes treatment success (> 25% improvement in pain or function) compared with placebo at 3 months' follow‐up (very low certainty).

1 finding from 1 review

Autologous blood or PRP vs placebo at 3 months' follow‐up

Adverse events (pain and swelling at injection site and limitation of elbow movement following injection) · lateral elbow pain

Autologous blood or PRP showed no clear difference in adverse events (pain and swelling at injection site and limitation… compared with placebo at 3 months' follow‐up (low certainty).

1 finding from 1 review